Abstract
Background and Aims: Patients with homozygous familial hypercholesterolemia (HoFH) have severely elevated LDL-C levels despite the use of multiple pharmacologic lipid-lowering therapies and often require lipid-apheresis. Evinacumab, an ANGPTL3 inhibitor with LDLR-independent activity, has been shown to reduce LDL-C in HoFH patients. To ascertain the impact of lipid-apheresis on circulating drug levels, we conducted an ex-vivo study evaluating the effect of lipid-apheresis on the recovery of evinacumab and ANGPTL3.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
